If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Correspondence: Dr. Andrés Wiscovitch, Oral and Maxillofacial Surgery Department, University of Puerto Rico – Medical Sciences Campus. Paseo Dr. José Celso Barbosa, San Juan, PR, 00921.Phone (727)235-3912.
PGY III, Oral and Maxillofacial Surgery Department, School of Dental Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PRResearch Department, Institución Universitaria Colegios de Colombia, Bogota, Colombia
Ameloblastomas are aggressive odontogenic entities well-known for their high tendency
to recur. Clinical presentation includes lesions discovered on routine examination
or radiographs, pathologies causing facial swelling, pain, cortical expansion, tooth
mobility, root resorption, and paresthesia. Radiographic findings comprise large unilocular
or multilocular radiolucencies with well-defined borders associated to an impacted
tooth. Ameloblastomas are classified as unicystic, multicystic/solid, and peripheral.
Treatment options include marsupialization, decompression, enucleation, or curettage
with or without adjuvant measures such as Carnoy's solution, marginal resection, and
segmental resection. Recently, Active Decompression with Distraction Sugosteogenesis
(ADDS) was introduced for the conservative management of odontogenic cystic conditions.
The purpose of this paper is to present two cases of a conventional ameloblastoma
treated by means of ADDS. This is a novel approach whose purpose is to significantly
reduce the amount of time required to decompress cystic like lesions. In these cases,
ADDS proved to be a viable treatment as it demonstrated a reduction in size of the
initial lesion by new osseous formation within 2 weeks of placement of the device.
The cases presented in this paper demonstrate that ADDS could be a valuable treatment
modality for this type of ameloblastomas, although further research is necessary to
validate this philosophy.